TY - JOUR
T1 - Evolving therapeutic proteins to precisely kill cancer cells
AU - Zaman, Rahela
AU - Islam, Rowshan Ara
AU - Chowdhury, Ezharul Hoque
N1 - Funding Information:
The authors like to thank Hamed Al-busaidi, Mahnoor Ummul-Warah Faateemah Zehra Mosaheb and Emranul Karim for their help with library resource allocation for this manuscript. This project was financially supported by a grant from Ministry of Higher Education, Malaysia (MoHE) ( FRGS/1/2018/STG05/MUSM/02/3 ).
Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022/11
Y1 - 2022/11
N2 - The established cancer treatment strategy in clinical setting is based on chemo and radiation therapy, having limitations due to severe side-effects and drug-resistance. Small molecule chemo-drugs target any fast-dividing cells irrespective of healthy or defective origin. As a result, a substantial amount of healthy tissue is also destroyed. Moreover, failure to recognize the heterogeneity of tumour tissue results in drug-resistance over the course of time. On the other hand, peptides and proteins actively target somatic changes that are signature to any specific tumour tissue. Development and metastasis of cancer cells require unique disruption/alteration of protein activity. Identification of those wild and cancerous genotypes and phenotypes is the key to establishing easy ‘targets’ for protein based targeted therapeutics. The approach is cytostatic and tissue specific, which reduces drug toxicity. Biopharmaceutical products based on proteins and peptides are slowly re-directing oncology from cytotoxic small molecular treatment approach to target oriented cytostatic strategy. This review focuses on current and upcoming peptide and protein-based precision therapeutics. At the same time, the study also shades light on the technological advancement in the field of protein and peptide-based therapeutics.
AB - The established cancer treatment strategy in clinical setting is based on chemo and radiation therapy, having limitations due to severe side-effects and drug-resistance. Small molecule chemo-drugs target any fast-dividing cells irrespective of healthy or defective origin. As a result, a substantial amount of healthy tissue is also destroyed. Moreover, failure to recognize the heterogeneity of tumour tissue results in drug-resistance over the course of time. On the other hand, peptides and proteins actively target somatic changes that are signature to any specific tumour tissue. Development and metastasis of cancer cells require unique disruption/alteration of protein activity. Identification of those wild and cancerous genotypes and phenotypes is the key to establishing easy ‘targets’ for protein based targeted therapeutics. The approach is cytostatic and tissue specific, which reduces drug toxicity. Biopharmaceutical products based on proteins and peptides are slowly re-directing oncology from cytotoxic small molecular treatment approach to target oriented cytostatic strategy. This review focuses on current and upcoming peptide and protein-based precision therapeutics. At the same time, the study also shades light on the technological advancement in the field of protein and peptide-based therapeutics.
KW - Antibody therapeutics
KW - Cancer
KW - Protein & peptide therapeutic
KW - Targeted therapeutic
UR - http://www.scopus.com/inward/record.url?scp=85139591105&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2022.09.066
DO - 10.1016/j.jconrel.2022.09.066
M3 - Review Article
C2 - 36202153
AN - SCOPUS:85139591105
VL - 351
SP - 779
EP - 804
JO - Journal of Controlled Release
JF - Journal of Controlled Release
SN - 0168-3659
ER -
